Hyderabad: Bharat Biotech was working on developing the COVID-19 vaccine as a top priority to ensure product availability at the earliest. The covid vaccine development of BBIL was faced with multiple challenges and all organisations were in a rush to develop vaccines and file the appropriate patents, prior to any other entity or prior to any data being published in journals.

Bharat Biotech’s covid vaccine application was filed in above circumstances and since BBIL-ICMR agreement copy, being a confidential document, was not accessible. Hence ICMR was not included in the original application. Though this was purely unintentional, such mistakes are not uncommon for the Patent office therefore Patent Law provides provisions to rectify such mistakes.

BBIL has great respect for ICMR and is thankful to ICMR for their continuous support on various projects therefore as soon as this inadvertent mistake was noticed, BBIL has already started the process to rectify it by including ICMR as co-owner of the patent applications for COVID-19 vaccine. Necessary legal documents are being prepared for it and BBIL will file those documents in Patent office as soon as those are ready and signed. These actions are in accordance with the memorandum of understanding (MoU) signed between ICMR-NIV Pune and BBIL for joint development of COVID-19 vaccine in April 2020.

  • Published On Jun 23, 2024 at 12:39 PM IST

Join the community of 2M+ industry professionals

Subscribe to our newsletter to get latest insights & analysis.

Download ETHealthworld App

  • Get Realtime updates
  • Save your favourite articles


Scan to download App